The estimated Net Worth of Olivier Danos is at least $2.03 Milion dollars as of 15 April 2019. Olivier Danos owns over 2,000 units of Regenxbio Inc stock worth over $108,035 and over the last 8 years he sold RGNX stock worth over $0. In addition, he makes $1,926,420 as Senior Vice President i Chief Scientific Officer at Regenxbio Inc.
Olivier has made over 4 trades of the Regenxbio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of RGNX stock worth $40,700 on 15 April 2019.
The largest trade he's ever made was exercising 20,000 units of Regenxbio Inc stock on 8 October 2018 worth over $407,000. On average, Olivier trades about 2,192 units every 15 days since 2017. As of 15 April 2019 he still owns at least 8,500 units of Regenxbio Inc stock.
You can see the complete history of Olivier Danos stock trades at the bottom of the page.
Dr. Olivier Danos Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. He has been our Chief Scientific Officer since March 2017. Prior to joining us, Dr. Danos was the Senior Vice President, Cell and Gene Therapy at Biogen Inc., a biotechnology company, from September 2014 until March 2017, where he led its gene therapy research and development activities. From September 2011 to September 2014, Dr. Danos was the Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Prior to Kadmon, Dr. Danos served as the Director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital—Enfants Malades in Paris. He also served as the Chief Scientific Officer at Genethon and Senior Director of Research at Somatix Therapy Corporation, and held senior roles at the French National Centre for Scientific Research and the Pasteur Institute in Paris. Dr. Danos is the former President and founding member of the European Society of Gene and Cell Therapy. Dr. Danos received a Ph.D. in Biology from the Pasteur Institute and University of Paris Diderot and a Master in Science in Genetics and Molecular Biology at the University of Paris Orsay.
As the Senior Vice President i Chief Scientific Officer of Regenxbio Inc, the total compensation of Olivier Danos at Regenxbio Inc is $1,926,420. There are 3 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
Olivier Danos is 62, he's been the Senior Vice President i Chief Scientific Officer of Regenxbio Inc since 2017. There are 7 older and 11 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
Olivier's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas oraz Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: